Translational expression analysis confirmed the decrease in PARP-1, HMGB1 and LC3I/II levels following the combinational treatment of CP-Mh, revealing that Mh exerts a therapeutic efficacy against HCC in the combination of CP chemotherapy. The gene discussed is HMGB1; the disease is hepatocellular carcinoma.